<DOC>
	<DOCNO>NCT01918098</DOCNO>
	<brief_summary>To determine improvement symptom constipation subject receive treatment oxycodone/naloxone prolong release tablet ( OXN ) compare oxycodone prolong release tablet ( OXY ) base Bowel Function Index ( BFI )</brief_summary>
	<brief_title>Targin Non-cancer Pain</brief_title>
	<detailed_description />
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Screening Inclusion criterion : Males female , 18 year age old Clinical diagnosis musculoskeletal pain 4 week longer nonmalignant pain etiology Visit 1 . Possible etiology condition related intervertebral disc disease , spondylolisthesis osteoarthritis ; similar nonmalignant disease also eligible . Patients nonmalignant pain require aroundtheclock opioid therapy ( oxycodone equivalent ≥10 mg/day ≤50 mg/day ) likely benefit WHO step III opioid therapy duration study Patients already treat NSAIDs least 2 week enrolment also eligible , rate pain ( Pain Intensity Scale `` average pain '' last 24 hour ) ≥4 010 scale . '' Subjects either take opioid medication willing take opioids treat pain Patients willing use adequate reliable contraception throughout study . Highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly sterilization , implant , injectable , combined oral contraceptive , IUDs ( intrauterine Device , hormonal ) , sexual abstinence vasectomize partner Subjects willing able participate aspect study , include use oral medication , completion subjective evaluation , attend schedule clinic visit , complete telephone contact , compliance protocol requirement evidence provide write informed consent Subjects take prestudy , nonopioid analgesic , concomitant medication , include medication treatment depression consider necessary subject 's welfare , anticipate remain stable throughout doubleblind period study , continue supervision investigator , eligible . Patients already treated NSAIDs least 2 week enrolment also eligible , rate pain ( Pain Intensity Scale `` average pain '' last 24 hour ) ≥4 010 scale . Criteria entry DoubleBlind phase : 1 . Subjects continue satisfy screen criterion outline protocol 2 . Subject 's OXY dose 1050 mg/day 3 . Subjects rate pain ( Pain Intensity Scale `` average pain '' last 24 hour ) as≤4 010 scale less equal two dos Morphine Sulfate tablet rescue medication per day either last three consecutive day four last seven day 4 . Subjects constipation induce , worsen opioid study medication , show : 1 . The subject 's medical need regular intake laxative least 3 bowel evacuation per week , le 3 bowel evacuation per week take laxative , respectively 2 . The subject ' constipation consider induced , worsen maintain current study opioid medication 3 . BFI value &gt; 30 . 5 . Subjects demonstrate compliance laxative use , complete appropriate legible daily diary 6 . Subjects take daily fibre supplementation bulk agent eligible maintain stable dose regimen throughout study , investigator 's opinion willing able maintain adequate hydration . Screening Exclusion criterion : 1 . Females pregnant ( positive βhCG test ) lactate 2 . Any history hypersensitivity contraindication oxycodone , naloxone , bisacodyl , relate product 3 . Subjects currently take equivalent &gt; 50 mg/day Oxycodone PR 4 . Evidence clinically significant cardiovascular , renal , hepatic , gastrointestinal ( paralytic ileus ) , psychiatric disease , determine medical history , clinical laboratory test , electrocardiogram ( ECG ) result , physical examination , place subject risk upon exposure study medication could confound analysis and/or interpretation study result 5 . Subjects evidence impair liver/kidney function upon entry study define aspartate aminotransferase ( AST ; SGOT ) , alanine aminotransferase ( ALT ; SGPT ) , alkaline phosphatase level &gt; 3 time upper limit normal ; gamma glutamyltranspeptidase ( GGT GGTP ) ≥ 5 time upper limit normal ; total bilirubin level outside reference range ; and/or creatinine level outside reference range &gt; 2 mg/dl , investigator 's opinion , liver and/or kidney impairment extent subject participate study 6 . Subjects evidence significant structural abnormality gastrointestinal tract diseases/conditions affect bowel transit 7 . Subjects require treatment diagnosis irritable bowel syndrome ( IBS ) 8 . Subjects receive hypnotic central nervous system ( CNS ) depressant , investigator 's opinion , may pose risk additional CNS depression opioids study medication 9 . Surgery within 2 month prior start Screening Period , plan surgery 12week Doubleblind Phase may affect GI motility pain 10 . Subjects diagnose cancer , include basal cell carcinoma 11 . Subjects Rheumatoid Arthritis ( RA ) 12 . Subjects receive opioid substitution therapy opioid addiction ( e.g. , methadone buprenorphine ) 13 . Subjects active alcohol drug abuse and/or history opioid abuse 14 . Subjects participate clinical research study involve new chemical entity experimental drug within 30 day study entry ( defined start Screening Period ) 15 . Subjects presently take , take naloxone naltrexone within 30 day study entry ( defined start Screening Period ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>